J&J's strongest talc settlement push yet could clear legal cloud
JNJ•Analysts see a path toward clearing an outstanding liability
J.P. Morgan (�neutral") sees this news as another step toward resolving this "outstanding liability" following the outperformance of the company's core business, noting that every $5 billion of liability amounts to less than 1% of JNJ's market capitalization.
RBC ("outperform") says the proposed $5.5 billion settlement is "materially below" what J&J was prepared to pay under the failed bankruptcy strategy, with the first payment of up to $3 billion due in 2027 and no further payments before 2028.
RBC adds that successful plaintiff participation could shift investor focus back to core operating fundamentals, including growth in the Innovative Medicines portfolio.
J&J's talc settlement proposal could resolve long-running litigation
Johnson & Johnson said on Monday it would pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc products caused ovarian cancer.
Shares of the drugmaker were up 2.6% before the bell.
Brokerages point to improved negotiating position and possible stock catalyst
Leerink ("outperform") says J&J appeared to be negotiating from its "strongest position yet in the decade-long talc litigation" after recent court developments weakened plaintiffs' causation case, helping the company secure a proposed settlement far below its previous offer.
